GlassScriptPhysician profile
Kialy Ann Mudd
NPI 1063015329
$1,725.64
in general payments reported to CMS, 2019-2025
19 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.49 · 2023: $55.78 · 2024: $636 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.94 | 2024-2025 | |
| Pfizer INC. | $188.33 | 2024-2025 | |
| Lilly USA, LLC | $165.96 | 2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $164.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $132.23 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $128.86 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $71.18 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.99 | 2024-2025 | Xifaxan |
| Amgen INC. | $57.80 | 2024 | Repatha, Otezla |
| Boston Scientific Corporation | $51.75 | 2022-2025 | Intracept |
| Sanofi-Aventis U.S. LLC | $45.62 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $44.49 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $41.45 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $28.97 | 2025 | Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.82 | 2025 | Caplyta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $21.91 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $18.87 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $17.06 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kialy Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.